Supplementary Methods
Herringbone microfluidic chip fabrication for rare circulating tumor cell capture
The herringbone microfluidic chips employed for rare cell capture were fabricated based on previous studies. (1, 2) The patterned silicon mold was produced by a standard two-step photolithographic process. In the first step, a thick layer (50 μm) of negative photoresist (SU8-2050, MicroChem Corp., USA) was spin-coated onto a 4-inch silicon wafer. After UV exposure and development, a serpentine fluidic channel with rectangular shape in the cross section was obtained (length 200 mm and width 1.0 mm). In the second step, another layer (50 μm) of SU8-2050 was spin-coated on the same wafer. Prior to the UV exposure the second mask was aligned to ensure a good alignment between the previous pattern and the pattern to be fabricated. To facilitate the separation between the replicate and molded poly(dimethylsiloxane) (PDMS) component, the replicate was treated by trimethylchlorosilane (TMCS, Sigma-Aldrich, USA). The PDMS pre-polymer (Sylgard 184, Dow Corning, USA) was mixed in a ratio of 10:1, and subsequently casted on this lithographically patterned replicate. After curing at 80°C for 2 h, the PDMS component was separated from the replicate, followed by trimming and hole introduction.
To chemically modify the PDMS device, the microfluidic channels were treated with O 2 plasma (PDC-32G, Harrick Plasma, USA) to create silanol groups, followed by treatment of 4% (v/v) solution of (3-Aminopropyl)trimethoxysilane (Sigma-Aldrich, USA) in ethanol for 1 h at room temperature.
Finally, the amoni-group-modified PDMS chip was thermally bonded to a poly-L-Lysine (PLL) coated glass slide (Thermo Fisher Scientific Inc., USA). A holder composed of two pieces of polyacrylate plates was home-machined to sandwich the PDMS chip and the glass slide substrate. Then the holder sandwiched these two parts by screws at the four corners of plastic plates. Two through-holes were drilled on the plastic plate (top) with a good alignment to the inlet and outlet holes of the PDMS chip, thus allowing convenience connection of tubing to the microfluidic channel of the chip. The complete assembly was capable of enduring back pressure of about 10 psi on the tested fluid samples without leaking.
2
To immobilize DNA on the internal wall of the device (including glass substrate and PDMS slab), a mixture (1:1 v/v) of amine-modified DNA solution (300 μM, in DMSO) and 2mM BS3 solution (in PBS, Thermo Scientific, USA) was filled into the device and flowed for 1.5 hours. The device was then stored in a sealed Petri dish with damp cotton for 1.5 hours, followed by washing with 0.02% SDS (in water) and deionized Millipore water. BS3 crosslinks amine-modified DNA with glass substrate and PDMS that are also modified with amine groups.
Spiral microfluidic chip fabrication for depletion of red blood cells
The spiral chip was fabricated in PDMS using standard microfabrication soft-lithographic techniques described previously for depletion of red blood cell. (3, 4) Briefly, a replicate for molding of PDMS was obtained by pattering a silicon wafer using photoresist SU-8 2100. The chip design consisted of a single inlet and triple-outlet spiral microchannel with 500 μm in width and 150 μm in height. The replicate was treated by TMCS to facilitate separation between the replicate and molded PDMS component. The PDMS pre-polymer was mixed in a ratio of 10:1, and subsequently casted on this lithographically patterned replicate. After curing at 80 °C for 2 h, the PDMS component was separated from the replicate, followed by trimming and hole introduction. The finished PDMS component was treated with oxygen plasma (PDC-32G, Harrick Plasma, USA) for bonding onto a glass slide. Finally, the microfluidic chip was treated at 70 °C for one week to make PDMS surface hydrophobic.
Fabrication of single-cell barcode chip (SCBC)
The SCBC was assembled from a DNA barcode microarray glass slide and a PDMS slab containing a microfluidic circuit. (5, 6) The PDMS microfluidic chip for the single-cell experiment was fabricated using a two-layer soft lithography approach. A push-down valve configuration was utilized with a thick control layer bonded to a thin flow layer underneath. The control layer was molded from a SU8 2025 negative photoresist (~40 μm in thickness) silicon master using a mixture of PDMS (RTV615, GE Toshiba Silicones Co. Ltd., USA) pre-polymer part A and part B (10:1). The flow layer was fabricated by spin-casting the pre-polymer of PDMS part A and part B (20:1) onto a SPR220-7 positive photoresist (Rohm Haas, USA) master at ~2000 rpm for 1 minute. The SPR 220 mold was ~10 μm in height, and these patterns were rounded via thermal treatment to allow complete valve closure. The control layer PDMS chip was then carefully aligned and placed onto the flow layer, which was still situated on its silicon master mold, and an additional 60 min thermal treatment at 80°C was performed to enable bonding. Afterward, this two-layer PDMS chip was cut off and access holes drilled. Finally, the microfluidic-containing PDMS slab was thermally bonded onto the barcode-patterned glass slide to 3 give a fully assembled microchip. The barcode-patterned glass slide is composed of DNA barcode for detection of secreted proteins and polylysine patterns for on-chip cell capture.
Microfluidic chip fabrication for barcode patterning
The barcode patterns for single-cell secretion profiling and on-chip cell capture were created with microchannel-guided flow patterning. The barcode patterning chips were fabricated based on previous studies. (5, 6) The mixture of PDMS pre-polymer and curing agent in 10:1 ratio (w/w) was poured onto the SU8-2015 negative photoresist mold with a 20-microchannels array (20 m in width and 30 m in height) and cured at 80°C for 1 hour. The cured PDMS slab was released from the mold, inlet/outlet holes punched, and thermally bonded onto a PLL-coated glass slide to form enclosed channels.
Fabrication of DNA and PLL barcodes
The DNA and PLL barcodes pattern were created with microchannel-guided flow patterning. After bonding of PDMS device to the PLL-coated glass substrate, a library of DNA solutions (C, D, and M), diluted in a mixture of DMSO and deionized water (v/v=1:2) with a final concentration of 267 μM, as well as 0.2 w/v% PLL solution (Mw≥300,000, Sigma-Aldrich) were flowed into each of the microfluidic channels. The solution-filled chip was placed in a desiccator to allow solvent (DMSO and water) to evaporate completely through the gas-permeable PDMS, leaving the DNA and PLL molecules behind. This evaporation process took 2~3 days to complete. Lastly, the PDMS elastomer was removed from the glass slide, and the barcode-patterned DNA was cross-linked to the glass surface by thermal treatment at 80°C for 4 hours. Residual crystals were readily removed by rapidly dipping the slide in deionized water, followed by blow-dry with nitrogen gun. This glass substrate with DNA and PLL barcodes were then ready for bonding with a SCBC.
DNA barcode validation
Each DNA barcode chip needs validation before bonding to the single-cell assay chip. A small area close to the edge was validated to check the DNA loading and uniformity. To do this, fluorescent Cy3-labeled complementary DNAs in 1% Bovine Serum Albumin (BSA, Sigma-Alrich)/ phosphatebuffered saline (PBS) were hybridized for 1 hr. After washing three times with 1% BSA/PBS and PBS, the slide was dried by nitrogen gun and scanned by GenePix 4400A (Molecular Device, USA, see Fig.   S2 ). Under laser power of 10% and gain of 400, fluorescence intensity above 15,000 was acceptable for CTC capture in herringbone chip and detection of secreted proteins in SCBC.
Antibody-ssDNA conjugation and validation
As-received antibodies (see Table S1 ) were desalted, buffer exchanged to pH 7.4 PBS and concentrated to 1 mg/mL using Zeba protein desalting spin columns (Thermo Fisher Scientific Inc., USA). Succinimidyl 4-hydrazinonicotinate acetone hydrazine (SANH, Solulink, USA) in N,Ndimethylformamide (DMF) was added to the antibodies at variable molar excess of (200:1) of SANH to antibody. Separately, succinimidyl 4-formylbenzoate (SFB, Solulink, USA) in DMF was added at a 16-fold molar excess to 5'aminated 30 mer oligomers in PBS. After incubation for 4 hours at room temperature, excessive SANH and SFB were removed by buffer exchange of both samples to pH 6.0 citrate buffer using protein desalting spin columns. A 30-fold excess of derivative DNA was then combined with the antibody and allowed to react 2 hours at room temperature followed by overnight Analysis of cell viability after on-chip release assisted by brief UV irradiation was conducted by staining on a cell settling chamber described by Ozkumur et al. (7) A simple PDMS chamber was fabricated and adhered to the PLL-coated glass slide. The released cells were loaded into the chamber and settled onto the glass surface via gentle centrifugation to generate a cell monolayer. Live/dead viability/cytotoxicity kit (Life Technologies, USA) was applied on the cells to check the cell viability.
Live and dead cells were visualized and counted with a Nikon Eclipse Ti scope.
Protocol for isolation and purification of CTCs spiked into blood samples
In this study, anti-coagulant-containing human whole blood from healthy donors was obtained from
Ruijin hospital affiliated to School of Medicine, Shanghai Jiao Tong University (Shanghai, China). The healthy donor blood samples were obtained with patient-informed consent under Ruijin hospital review board approval. According to a standard protocol, all blood samples were collected into EDTAcontained vacutainer tubes and were processed within 8 h. To demonstrate the performance of the integrated microfluidics system, cultured EpCAM-positive tumor cells (HCT116) were spiked into whole blood from healthy donors as the model system. For experiments using lysed blood, RBC lysis buffer (Beyotime, China) was added to whole blood in 10:1 v/v ratio and mixed for 5 min at RT. After 5-min centrifugation at 500 g, the supernatant was discarded and the cell pellet was washed twice with PBS and then re-suspended in an equivalent volume of buffer for capture experiments.
In demonstrating performance, ~200 cells were spiked into 1 mL of whole blood in triplicate. CTCs and WBCs were collected at the outlet 2 and 3 (see Fig. S13 ) and flowed through a microfluidic chip and an array of magnets were used to deplete WBCs. (8) The remaining cells were finally transported to a PLL-patterned SCBC for on-chip secretion profiling. Importantly, microchannels in spiral chip and WBC depletion chip, as well as tubing and pins were pre-blocked with 1% BSA to prevent non-specific adsorption. 
CTC isolation and identification in lung cancer patient samples
The CTC capture and enumeration from cancer patient samples was performed in a similar procedure to that described above. Blood samples were obtained from healthy donors and metastatic lung cancer patients with informed consent, which has been approved by the Ethics and Scientific Committee of our Institution. A total of 10 blood samples (4 from lung cancer patients and 6 from healthy donors) were obtained at the middle of vein puncture after first 3 mL of blood was discarded.
According to a standard protocol, all blood samples (4 mL taken from patients, and 2 mL taken from healthy donors) were collected into EDTA-contained vacutainer tubes and were processed within 6 h.
A volume of 4 mL peripheral blood from patients was equally divided into two parts for CTC enumeration and single-cell secretion profiling. Briefly, 4 mL of blood was centrifuged to remove the plasma and re-suspended in 0.1% BSA/PBS to generate a 4 mL cell suspension. It is worth to note that removal of plasma from patient blood samples before mixing with conjugates is necessary to increase precision of measurements, although we used whole blood from healthy donors in the proof-of-concept experiments. Cell suspensions were then actively incubated with a cocktail of photocleavable ssDNAantibody conjugates (PC-M'-EpCAM, PC-M'-EGFR, PC-M'-HER2 and PC-M'-CD44). Excessive conjugates in the supernatant were then removed by centrifugation, and cells were re-suspened in in 0.1% BSA/PBS to generate a new 4 mL cell suspension. The 4 mL cell suspension was equally split into two parts. A herringbone chip with a 400 mm-long microvotex-generating channel was employed to capture CTCs from cell suspensions. For the first 2 mL of cell suspension, CTCs were captured on the chip followed by enumeration based on traditional CK+/CD45-/DAPI+ stain criteria. For another 2 mL of cell suspension, CTCs were captured, released and transported to SCBC for secretome profiling.
All steps were as same as described in proof-of-concept experiments (see Supplementary Methods 9).
For control experiments, 2 mL blood samples from healthy donors were centrifuged to remove plasma, followed by the same procedure described above. CTC enumeration was based on CK+/CD45-/DAPI+ stain criteria.
Protocol for detection of secreted proteins from rare tumor cells using SCBC with a PLL
barcode pattern 8 a) Prior to cell loading, all microfluidic channels were blocked with a blocking buffer (3% BSA in PBS) for 60 minutes to prevent non-specific binding.
b) After blocking, a 100 l cocktail containing all DNA-antibody conjugates at 10 μg/ml in working buffer (1% BSA in PBS) was flowed through the micro-channels for 1 hour. Unbound DNA-antibody conjugates were washed away with 20 l of working buffer.
c) Rare tumor cells collected from WBC depletion chip were flowed into the channels from outlets of the SCBC 2.0. Tumor cells were then captured by polylysine stripes localized in the middle of micro-chambers of the SCBC. A control valve was then activated at 20 psi to partition the channel into multiple discrete chambers. Images of each chamber were recorded using a CCD camera, and used later for cell counting.
d) The device was then placed in an incubator in humidified atmosphere of 5% CO 2 and 95% air at 37°C for 6 hours to allow cellular secretions to accumulate. e) Afterwards, the control valve was released and a rapid flush was conducted to wash off cells and unbound secreted molecules with working buffer. A 100 l cocktail containing biotin-labeled detection antibodies in working buffer at a concentration specified in the insert of that ELISA kit (See Table S1 for reagents. The concentration varies from lot to lot) was then flowed through the microchannels. Unbound detection antibodies were then flushed out by flowing the working buffer for 10 minutes.
f) A 100 l mixture of 2 g/ml Cy5-labeled straptavidin (eBioscience, USA) and 50 nM Cy3-labeled M' ssDNA in working buffer was flowed through the microchannels.to complete the immune sandwich assay.
g) Finally, the microchannels were rinsed with working buffer and PBST. The PDMS chip was removed, and the bare microarray slide was rinsed sequentially with 1PBS, 0.5PBS, and deionized
Millipore water before spin-drying.
h) Optical readout: The slide was scanned by a GenePix 4400A (Molecular Devices) at laser power 80% (635nm) and 10% (532nm), and at 2.5 μm/pixel resolution. Signals from two color channels (the green Cy3 and the red Cy5) were collected and the average fluorescence signals from each barcode were extracted by a custom MATLAB (The Mathworks) code for further analysis.
Data analysis
The microarray slides (barcode microarray and spot microarray) were scanned with a GenePix 4400A (Molecular Devices, USA) to obtain a fluorescence image for both Cy3 and Cy5 dyes. Millipore. Red blood cell lysis buffer was obtained from Beyotime (China). UV bench lamp (6 watts, 365 nm, Intensity 1200 μW/cm 2 ) was purchased from Cole-Parmer. Table S1 . ssDNAs and antibodies used in this study. The upper part of the table provides the sequences of the oligonucleotides used in the protein immunoassays. All oligonucleotides were synthesized by Sangon Biotech (Shanghai, China) and purified via high performance liquid chromatography (HPLC).
The DNA coding oligomers were pre-tested for orthogonality to ensure that cross-hybridization between non-complementary oligomer strands was negligible (<1% in photon counts). Below the oligonucleotides is a list of the antibodies and standard proteins used for the multiplex protein assay.
Name DNA sequence Source A GenePix 4400A (Molecular Devices) array scanner was used to obtain this image in the 532nm channel with a laser power set at 10% and an optical gain of 400. This data reflects the uniform DNA loading (~20,000) across the whole slide. Each DNA-immobilized glass substrates and PDMS herringbone chips were validated before bonding. The DNA barcode microarrays for SCBC assays were validated in a similar way, which was described before (6). Figure S21 . Scatter plots of IL-8 versus VEGF derived from SCBC measurements on CTCs that were isolated and purified from patients' 2 mL blood samples.
